T1	Participants 145 189	38 patients with progressive IgA nephropathy
T2	Participants 542 557	treatment group
T3	Participants 1276 1284	patients
T4	Participants 1494 1522	treatment and control groups
T5	Participants 1603 1611	patients
T6	Participants 1720 1732	both groups;
T7	Participants 1880 1888	Patients
